To contextualise these findings, in an experimental model of T2D, the administration of tofacitinib significantly decreased HOMA-IR and glycaemia, simultaneously improving glucose homeostasis, insulin secretion, and HOMA2-β [22]. Here, INS is linked to type 2 diabetes mellitus.